Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niccolò Bolli

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Blood|June 25, 2026
In search of dependencies in myeloma, consider IRF2 tooElisa Taiana, Niccolò Bolli
Blood|January 30, 2025
For how long has this problem been there?Niccolò Bolli, Matteo Claudio da Vià
Hematology Reports|January 7, 2021
The molecular pathogenesis of multiple myelomaNiccolò Bolli, Giovanni Martinelli, Claudio Cerchione
Cancers|July 9, 2022
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas"Antonio Giovanni Solimando, Matteo Claudio Da Vià, Niccolò Bolli, et al.
JAMA Oncology|December 13, 2019
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A ReviewFrancesco Maura, Niccolò Bolli, Even H Rustad, et al.
Cancers|July 20, 2021
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?Marta Lionetti, Matteo C Da Vià, Francesco Albano, et al.
Hemasphere|December 7, 2020
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease ComplexityMatteo C Da Vià, Bachisio Ziccheddu, Akihiro Maeda, et al.
Cancer Gene Therapy|March 17, 2024
The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancersDomenica Ronchetti, Valentina Traini, Ilaria Silvestris, et al.
The Lancet. Oncology|January 1, 2004
Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapyNiccolò Bolli, Mauro Di Ianni, Stefano Simonetti, et al.
Blood|October 30, 2010
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Brunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Blood|June 25, 2026
In search of dependencies in myeloma, consider IRF2 tooElisa Taiana, Niccolò Bolli
Blood|January 30, 2025
For how long has this problem been there?Niccolò Bolli, Matteo Claudio da Vià
Hematology Reports|January 7, 2021
The molecular pathogenesis of multiple myelomaNiccolò Bolli, Giovanni Martinelli, Claudio Cerchione
Cancers|July 9, 2022
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas"Antonio Giovanni Solimando, Matteo Claudio Da Vià, Niccolò Bolli, et al.
JAMA Oncology|December 13, 2019
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A ReviewFrancesco Maura, Niccolò Bolli, Even H Rustad, et al.
Cancers|July 20, 2021
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?Marta Lionetti, Matteo C Da Vià, Francesco Albano, et al.
Hemasphere|December 7, 2020
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease ComplexityMatteo C Da Vià, Bachisio Ziccheddu, Akihiro Maeda, et al.
Cancer Gene Therapy|March 17, 2024
The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancersDomenica Ronchetti, Valentina Traini, Ilaria Silvestris, et al.
The Lancet. Oncology|January 1, 2004
Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapyNiccolò Bolli, Mauro Di Ianni, Stefano Simonetti, et al.
Blood|October 30, 2010
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Brunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Pageof 10